Septerna, Inc.'s (NASDAQ:SEPN) Lock-Up Period Will End on April 23rd

Septerna's (NASDAQ:SEPN - Get Free Report) lock-up period is set to expire on Wednesday, April 23rd. Septerna had issued 16,000,000 shares in its public offering on October 25th. The total size of the offering was $288,000,000 based on an initial share price of $18.00. After the expiration of Septerna's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Wall Street Analyst Weigh In

SEPN has been the subject of several research reports. Wells Fargo & Company cut their target price on Septerna from $14.00 to $11.00 and set an "equal weight" rating for the company in a research note on Friday, March 28th. Cantor Fitzgerald restated an "overweight" rating and issued a $50.00 price objective on shares of Septerna in a report on Tuesday, February 11th.

Septerna Price Performance

SEPN stock traded down $0.09 during trading on Friday, hitting $5.90. 211,957 shares of the company traded hands, compared to its average volume of 439,031. The stock has a 50-day moving average of $6.45. Septerna has a 1 year low of $4.17 and a 1 year high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.64) earnings per share for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The company had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.13 million. Analysts anticipate that Septerna will post -7.11 EPS for the current year.

Insider Activity

In other Septerna news, CFO Gil M. Labrucherie bought 5,000 shares of the firm's stock in a transaction that occurred on Friday, February 21st. The stock was bought at an average price of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the acquisition, the chief financial officer now directly owns 30,000 shares in the company, valued at $175,500. The trade was a 20.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Alan Ezekowitz purchased 7,491 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was bought at an average price of $6.35 per share, for a total transaction of $47,567.85. Following the acquisition, the director now owns 24,911 shares of the company's stock, valued at $158,184.85. This represents a 43.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 74,346 shares of company stock valued at $439,670.

Institutional Trading of Septerna

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC bought a new position in shares of Septerna in the 4th quarter worth approximately $25,000. New York State Common Retirement Fund purchased a new stake in Septerna in the fourth quarter worth $32,000. Legal & General Group Plc bought a new position in Septerna in the fourth quarter worth $42,000. Summit Investment Advisors Inc. purchased a new position in Septerna during the fourth quarter valued at $45,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Septerna during the 4th quarter valued at $52,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.